Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kapil Bhalla

Showing results (131-140 of 153) with videos related to

Pageof 16
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|May 24, 2016
Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC)Courtney D DiNardo, Sarah A Bannon, Mark Routbort, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 1, 2005
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Haematologica|March 23, 2023
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)Guillaume Richard-Carpentier, Caitlin R Rausch, Koji Sasaki, et al.
Blood|September 19, 2025
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AMLReeja Raj, Samanta Catueno, Amber Gibson, et al.
American Journal of Hematology|March 31, 2012
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH SymposiumOmar Abdel-Wahab, Animesh Pardanani, Olivier A Bernard, et al.
Blood Advances|November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLGhayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.
American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Journal of Hematology & Oncology|November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemiasJayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
Frontiers in Oncology|February 15, 2021
Next-Generation Sequencing of <i>DDX41</i> in Myeloid Neoplasms Leads to Increased Detection of Germline AlterationsSarah A Bannon, Mark J Routbort, Guillermo Montalban-Bravo, et al.
Pageof 16

Showing results (131-140 of 153) with videos related to

Sort By:
Pageof 16
Clinical Lymphoma, Myeloma & Leukemia|May 24, 2016
Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC)Courtney D DiNardo, Sarah A Bannon, Mark Routbort, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 1, 2005
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Haematologica|March 23, 2023
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)Guillaume Richard-Carpentier, Caitlin R Rausch, Koji Sasaki, et al.
Blood|September 19, 2025
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AMLReeja Raj, Samanta Catueno, Amber Gibson, et al.
American Journal of Hematology|March 31, 2012
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH SymposiumOmar Abdel-Wahab, Animesh Pardanani, Olivier A Bernard, et al.
Blood Advances|November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLGhayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.
American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Journal of Hematology & Oncology|November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemiasJayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
Frontiers in Oncology|February 15, 2021
Next-Generation Sequencing of <i>DDX41</i> in Myeloid Neoplasms Leads to Increased Detection of Germline AlterationsSarah A Bannon, Mark J Routbort, Guillermo Montalban-Bravo, et al.
Pageof 16